AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Institutional & Insider Ownership
91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by insiders. Comparatively, 6.1% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares AirSculpt Technologies and Castle Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AirSculpt Technologies | $151.82 million | 0.77 | -$11.67 million | ($0.18) | -9.00 |
| Castle Biosciences | $344.23 million | 3.05 | -$24.16 million | ($0.66) | -52.15 |
AirSculpt Technologies has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than AirSculpt Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for AirSculpt Technologies and Castle Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AirSculpt Technologies | 1 | 1 | 0 | 0 | 1.50 |
| Castle Biosciences | 1 | 1 | 7 | 1 | 2.80 |
AirSculpt Technologies presently has a consensus target price of $4.50, suggesting a potential upside of 177.78%. Castle Biosciences has a consensus target price of $42.00, suggesting a potential upside of 22.02%. Given AirSculpt Technologies’ higher possible upside, analysts clearly believe AirSculpt Technologies is more favorable than Castle Biosciences.
Risk and Volatility
AirSculpt Technologies has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Profitability
This table compares AirSculpt Technologies and Castle Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AirSculpt Technologies | -7.79% | -5.83% | -2.88% |
| Castle Biosciences | -5.43% | -4.15% | -3.45% |
Summary
Castle Biosciences beats AirSculpt Technologies on 8 of the 15 factors compared between the two stocks.
About AirSculpt Technologies
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas. The company’s body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Receive News & Ratings for AirSculpt Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AirSculpt Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
